Novartis Kesimpta® six-year efficacy data show substantial …
WEBBasel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ® (ofatumumab) treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with ...
FDA approves Novartis Kesimpta® (ofatumumab), the first and …
WEBBasel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta ® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active ...
New Novartis data in relapsing MS reinforce benefits of …
WEB4 days ago · Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1 More than 80% of patients receiving first-line Kesimpta were progression-free for up to six years, reinforcing the value of introducing Kesimpta early1 Patients switching to Kesimpta from IV anti-CD20 therapy ...
Relapsing MS Treatment I KESIMPTA® (ofatumumab)
WEBKESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease. It is not known if KESIMPTA is …
FDA approves Novartis Kesimpta® (ofatumumab), the first and
WEBBasel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta ® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for...
Ofatumumab versus Teriflunomide in Multiple Sclerosis
WEBAug 5, 2020 · Anti-CD20 monoclonal antibodies that induce B-cell depletion, such as rituximab and ocrelizumab, are effective disease-modifying therapies for multiple sclerosis. 1-4 Ofatumumab, a fully human...
Kesimpta (ofatumumab) for MS: Uses, side effects, and more
WEBMar 15, 2022 · Kesimpta (ofatumumab) is an anti-CD20 antibody approved for the treatment of multiple sclerosis (MS). The Danish biotechnology company Genmab first developed the treatment and licensed it to...
New MS Drug Kesimpta May Help Keep Symptoms at Bay
WEBTHURSDAY, July 18, 2024 -- A new monoclonal antibody treatment called Kesimpta (ofatumumab) appears to improve on an older drug in pushing multiple sclerosis (MS) into remission, a new trial shows.
Novartis set to take on Roche as FDA clears first at-home, injectable ...
WEBAug 20, 2020 · The Food and Drug Administration on Thursday approved Kesimpta, formerly known as ofatumumab, a drug developed by Novartis for patients with the relapsing form of multiple sclerosis, the most common form of the disease.
FDA extends review of Novartis' MS drug ofatumumab
WEBAug 31, 2024 · The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year.
Skip to content